



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Qiongqiong Yang
yangqq@mail.sysu.edu.cn

[†]These authors have contributed
equally to this work

SPECIALTY SECTION
This article was submitted to
Autoimmune and Autoinflammatory
Disorders: Autoimmune Disorders,
a section of the journal
Frontiers in Immunology

RECEIVED 20 October 2022
ACCEPTED 21 October 2022
PUBLISHED 07 November 2022

CITATION
Wu J, Wei X, Li J, Gan Y, Zhang R,
Han Q, Liang P, Zeng Y and Yang Q
(2022) Corrigendum: Plasma exosomal
IRAK1 can be a potential biomarker for
predicting the treatment response to
renin-angiotensin system inhibitors in
patients with IgA nephropathy.
Front. Immunol. 13:1074864.
doi: 10.3389/fimmu.2022.1074864

COPYRIGHT
© 2022 Wu, Wei, Li, Gan, Zhang, Han,
Liang, Zeng and Yang. This is an open-
access article distributed under the
terms of the [Creative Commons
Attribution License \(CC BY\)](#). The use,
distribution or reproduction in other
forums is permitted, provided the
original author(s) and the copyright
owner(s) are credited and that the
original publication in this journal is
cited, in accordance with accepted
academic practice. No use,
distribution or reproduction is
permitted which does not comply with
these terms.

Corrigendum: Plasma exosomal IRAK1 can be a potential biomarker for predicting the treatment response to renin-angiotensin system inhibitors in patients with IgA nephropathy

Jianping Wu[†], Xiaona Wei[†], Jiajia Li, Yangang Gan, Rui Zhang, Qianqian Han, Peifen Liang, Yuchun Zeng and Qiongqiong Yang*

Department of Nephrology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China

KEYWORDS

IgA nephropathy, Renin-angiotensin system inhibitors, Exosome, Biomarker, Treatment response

A corrigendum on

Plasma exosomal IRAK1 can be a potential biomarker for predicting the treatment response to renin-angiotensin system inhibitors in patients with IgA nephropathy

by Wu J, Wei X, Li J, Gan Y, Zhang R, Han Q, Liang P, Zeng Y and Yang Q (2022) *Front. Immunol.* 13:978315. doi: 10.3389/fimmu.2022.978315

In the published article, the funding information was missing. The correct Funding statement appears below.

Funding

This project was funded by the National Key R&D Programme of China (2021YFC2009404); the Science and Technology Projects in Guangzhou (201904010142) and the Natural Science Foundation of Guangdong Province (2021A1515010801).

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.